Effects of adding L-arginine orally to standard therapy in patients with COVID-19: A randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis

BACKGROUND: We and others have previously demonstrated that the endothelium is a primary target of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and L-arginine has been shown to improve endothelial dysfunction. However, the effects of L-arginine have never been evaluated in coron...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiorentino, Giuseppe, Coppola, Antonietta, Izzo, Raffaele, Annunziata, Anna, Bernardo, Mariano, Lombardi, Angela, Trimarco, Valentina, Santulli, Gaetano, Trimarco, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428476/
https://www.ncbi.nlm.nih.gov/pubmed/34522871
http://dx.doi.org/10.1016/j.eclinm.2021.101125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428476/
https://www.ncbi.nlm.nih.gov/pubmed/34522871
http://dx.doi.org/10.1016/j.eclinm.2021.101125

Ejemplares similares